Další formáty:
BibTeX
LaTeX
RIS
@article{1089664, author = {Van Cutsem, Eric and Tabernero, Josep and Lakomý, Radek and Prenen, Hans and Prausová, Jana and Macarulla, Teresa and Ruff, Paul and van Hazel, Guy A. and Moiseyenko, Vladimir and Ferry, David and McKendrick, Joe and Polikoff, Jonathan and Tellier, Alexia and Castan, Remi and Allegra, Carmen}, article_location = {United States}, article_number = {28}, doi = {http://dx.doi.org/10.1200/JCO.2012.42.8201}, keywords = {ENDOTHELIAL GROWTH-FACTOR; ADVANCED SOLID TUMORS; VEGF-TRAP; ANGIOGENESIS; BEVACIZUMAB; CONSORTIUM; RECURRENT}, language = {eng}, issn = {0732-183X}, journal = {Journal of clinical oncology}, title = {Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen}, volume = {30}, year = {2012} }
TY - JOUR ID - 1089664 AU - Van Cutsem, Eric - Tabernero, Josep - Lakomý, Radek - Prenen, Hans - Prausová, Jana - Macarulla, Teresa - Ruff, Paul - van Hazel, Guy A. - Moiseyenko, Vladimir - Ferry, David - McKendrick, Joe - Polikoff, Jonathan - Tellier, Alexia - Castan, Remi - Allegra, Carmen PY - 2012 TI - Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen JF - Journal of clinical oncology VL - 30 IS - 28 SP - 3499-3506 EP - 3499-3506 PB - American Society of Clinical Oncology SN - 0732183X KW - ENDOTHELIAL GROWTH-FACTOR KW - ADVANCED SOLID TUMORS KW - VEGF-TRAP KW - ANGIOGENESIS KW - BEVACIZUMAB KW - CONSORTIUM KW - RECURRENT N2 - Purpose Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody. We studied the effect of adding the novel antiangiogenic agent aflibercept (also known as ziv-aflibercept in the United States) to FOLFIRI in patients with mCRC previously treated with oxaliplatin, including patients who received prior bevacizumab. Results Adding aflibercept to FOLFIRI significantly improved overall survival relative to placebo plus FOLFIRI (hazard ratio [HR], 0.817; 95.34% CI, 0.713 to 0.937; P = .0032) with median survival times of 13.50 versus 12.06 months, respectively. Aflibercept also significantly improved progression-free survival (PFS; HR, 0.758; 95% CI, 0.661 to 0.869; P < .0001), with median PFS times of 6.90 versus 4.67 months, respectively. The effects on overall survival and PFS exhibited a consistent trend across prespecified subgroup analyses, including bevacizumab pretreated patients. Response rate was 19.8% (95% CI, 16.4% to 23.2%) with aflibercept plus FOLFIRI compared with 11.1% (95% CI, 8.5% to 13.8%) with placebo plus FOLFIRI (P = .0001). Adverse effects reported with aflibercept combined with FOLFIRI included the characteristic anti-vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities. Conclusion Aflibercept in combination with FOLFIRI conferred a statistically significant survival benefit over FOLFIRI combined with placebo in patients with mCRC previously treated with oxaliplatin. J Clin Oncol 30:3499-3506. (C) 2012 by American Society of Clinical Oncology ER -
VAN CUTSEM, Eric, Josep TABERNERO, Radek LAKOMÝ, Hans PRENEN, Jana PRAUSOVÁ, Teresa MACARULLA, Paul RUFF, Guy A. VAN HAZEL, Vladimir MOISEYENKO, David FERRY, Joe MCKENDRICK, Jonathan POLIKOFF, Alexia TELLIER, Remi CASTAN a Carmen ALLEGRA. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. \textit{Journal of clinical oncology}. United States: American Society of Clinical Oncology, roč.~30, č.~28, s.~3499-3506. ISSN~0732-183X. doi:10.1200/JCO.2012.42.8201. 2012.
|